Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。